Omeros announces positive OMS302 safety data in Phase 3 clinical trial Omeros announced the successful completion of the 90-day safety database lock in the second of the company's two pivotal Phase 3 clinical trials evaluating OMS302 in patients undergoing intraocular lens replacement surgery. OMS302 is Omeros' proprietary PharmacoSurgery product designed to maintain intraoperative mydriasis and reduce postoperative pain and irritation resulting from cataract and other lens replacement surgery. Safety data were collected through postoperative day 90. In this Phase 3 clinical trial, OMS302 was well tolerated. No safety concerns have been identified in the OMS302 clinical development program.
News For OMER From The Last 14 Days
Check below for free stories on OMER the last two weeks.
Subscribe for More Information